BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 28, 2006
View Archived Issues
Encysive Shares Tumble On FDA Thelin Approvable Letter
Encysive Pharmaceuticals Inc. lost almost half its stock value Monday on news that the FDA may require additional clinical trial work for the pulmonary arterial hypertension drug Thelin. (BioWorld Today)
Read More
Corgentech’s Phase II Study With VR1 Agonist Negative
Read More
Keryx Pads Balance Sheet With $83M Direct Stock Sale
Read More
Systemic RNAi Data Leads To Alnylam Partnership With INEX
Read More
Clinic Roundup
Read More
Other News To Note
Read More